^
Association details:
| Biomarker: | GPC3 expression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug Class: | T-lymphocyte cell therapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin
Published date:
07/29/2021
Excerpt:
Subject GD-G/M-001 is an advanced HCC patient with GPC3 expression...the liver tumor lesion (1.2 × 1.3 cm) shrunk significantly on day 10 and completely disappeared on day 32 post anti-GPC3-7 × 19 CAR-T cells injection...The patient did not suffer any toxic effects and had staging evaluation revealing partial response (PR)...one PC patient (1/6, 16.7%) achieved CR; one HCC patient (1/6, 16.7%) achieved PR; and 2 (2/6, 33.3%) achieved steady disease (SD), demonstrating the huge therapeutic potential of 7 × 19 CAR-T cell therapy for advanced solid tumors with GPC3/MSLN expression.
DOI:
10.1186/s13045-021-01128-9
